Remove 2021 Remove Heart Failure Remove Preserved Ejection Fraction
article thumbnail

Heart failure services from the community perspective in the UK: a cross-sectional survey

The British Journal of Cardiology

Heart failure (HF) is a highly prevalent long-term condition, with variation in services and resources across the UK. This report provides findings from a cross-sectional survey of community HF services in the UK between September 2021 and February 2022. Eighty-five responses describing community HF services were received.

article thumbnail

Heart failure services from the hospital perspective in the UK: a cross-sectional survey

The British Journal of Cardiology

Heart failure (HF) is a significant problem in the UK with variation in services across the country. Here we describe the findings from a cross-sectional survey of HF services in the UK performed between September 2021 and February 2022. The clinical lead in 82% of hospitals was a cardiologist with specialist interest in HF.

article thumbnail

Characterisation of the octogenarians presenting to the diagnostic heart failure clinic: SHEAF registry

Open Heart

Introduction Heart failure (HF) incidence is increasing in older adults with high hospitalisation and mortality rates. Results Data were collected in April 2012 to January 2014 and in June 2021 to December 2022. Treatment is complicated by side effects and comorbidities. and 29.2%, p<0.001).

article thumbnail

Bayer to Present New Investigational Heart Failure Data, Continued Portfolio Research in Chronic Kidney Disease at ACC.25

DAIC

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).

article thumbnail

Bayer to Present New Investigational Heart Failure Data, Continued Portfolio Research

DAIC

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).

article thumbnail

Research Study on Novel Rehab Program for Heart Failure Patients, Led by Wake Forest University School of Medicine, Expands to Advocate Health Site in Chicago

DAIC

The study, which is testing a novel rehabilitation program designed for older patients hospitalized with acute heart failure, is funded by a five-year, $30 million grant , awarded to Wake Forest University School of Medicine in 2022 by the National Institute of Aging, part of the National Institutes of Health.

article thumbnail

Use of Sodium?Glucose Cotransporter?2 Inhibitors and Angiotensin Receptor?Neprilysin Inhibitors in Patients With Atrial Fibrillation and Heart Failure From 2021 to 2022: An Analysis of Real?World Data

Journal of the American Heart Association

BackgroundContemporary use of sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) and angiotensin receptor‐neprilysin inhibitors (ARNi) in patients with atrial fibrillation (AF) and heart failure (HF) has not been described.Methods and ResultsWe analyzed the MarketScan databases for the period January 1, 2021 to July 30, 2022.